MetaVia to present DA-1726 Phase 1 trial data at Precision Liver Symposium
MTVA•MetaVia will present Phase 1 trial results for DA-1726 at the Precision Liver Symposium on November 4, 2026, in Denver. The randomized, placebo-controlled trial showed significant reductions in liver fat and weight, with relative preservation of lean mass.
1. Trial results presentation
MetaVia will present Phase 1 trial results for DA-1726 at the Precision Liver Symposium on November 4, 2026, in Denver. The randomized, placebo-controlled trial showed significant reductions in liver fat and weight, with relative preservation of lean mass.
